Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DVAX NASDAQ:INVA NASDAQ:MNKD NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVAXDynavax Technologies$10.44-2.8%$10.04$9.22▼$14.63$1.29B1.032.15 million shs1.51 million shsINVAInnoviva$19.96+1.9%$19.84$16.67▼$22.00$1.23B0.37712,151 shs1.47 million shsMNKDMannKind$3.85-4.5%$4.06$3.51▼$7.63$1.22B0.962.44 million shs2.91 million shsRIGLRigel Pharmaceuticals$18.90-2.3%$19.51$8.61▼$29.82$345.83M1.26210,519 shs154,760 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVAXDynavax Technologies-2.79%-1.42%+1.66%-1.97%-1.14%INVAInnoviva+1.94%+4.72%-7.98%+10.34%+18.46%MNKDMannKind-4.47%+6.35%+3.77%-15.01%-33.96%RIGLRigel Pharmaceuticals-2.33%+2.61%-7.89%+14.61%+78.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDVAXDynavax Technologies4.4421 of 5 stars3.32.00.04.72.91.71.9INVAInnoviva4.0532 of 5 stars3.50.00.04.22.11.71.9MNKDMannKind2.7373 of 5 stars3.60.00.00.02.71.71.9RIGLRigel Pharmaceuticals3.068 of 5 stars3.20.00.00.02.61.73.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDVAXDynavax Technologies 2.50Moderate Buy$24.00129.89% UpsideINVAInnoviva 3.00Buy$40.33102.07% UpsideMNKDMannKind 3.29Buy$10.33168.40% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4092.59% UpsideCurrent Analyst Ratings BreakdownLatest RIGL, DVAX, INVA, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/11/2025INVAInnovivaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.005/7/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.004/17/2025DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$12.00 ➝ $10.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDVAXDynavax Technologies$277.25M4.52$0.15 per share67.82$4.54 per share2.30INVAInnoviva$358.71M3.49$3.49 per share5.72$11.03 per share1.81MNKDMannKind$297.60M3.93$0.13 per share29.04($0.29) per share-13.28RIGLRigel Pharmaceuticals$179.28M1.88$1.05 per share17.94$0.19 per share99.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDVAXDynavax Technologies$27.31M-$0.52N/A21.31N/A-20.39%3.59%2.20%8/5/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A12.88N/A-16.15%15.77%8.41%7/29/2025 (Estimated)MNKDMannKind$27.59M$0.1038.5016.74N/A10.12%-32.41%10.85%8/6/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$2.079.1318.00N/A18.31%-655.26%24.47%8/5/2025 (Estimated)Latest RIGL, DVAX, INVA, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MNKDMannKind$0.04N/AN/AN/A$77.82 millionN/A8/5/2025Q2 2025DVAXDynavax Technologies$0.12N/AN/AN/A$87.55 millionN/A8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.42N/AN/AN/A$64.58 millionN/A7/29/2025Q2 2025INVAInnoviva$0.43N/AN/AN/A$87.10 millionN/A5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDVAXDynavax TechnologiesN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDVAXDynavax Technologies0.4911.9310.84INVAInnoviva0.402.482.30MNKDMannKindN/A2.362.11RIGLRigel Pharmaceuticals2.422.202.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDVAXDynavax Technologies96.96%INVAInnoviva99.12%MNKDMannKind49.55%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipDVAXDynavax Technologies2.98%INVAInnoviva2.25%MNKDMannKind3.00%RIGLRigel Pharmaceuticals9.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDVAXDynavax Technologies350120.08 million116.50 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionableMNKDMannKind400303.93 million294.82 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.26 millionOptionableRIGL, DVAX, INVA, and MNKD HeadlinesRecent News About These CompaniesH.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL)July 10, 2025 | insidermonkey.comRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)July 7, 2025 | prnewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Hold" by BrokeragesJune 27, 2025 | marketbeat.comRIGL Rigel Pharmaceuticals, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comRigel Pharmaceuticals (NASDAQ:RIGL) shareholders have earned a 99% return over the last yearJune 21, 2025 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stake Boosted by GAMMA Investing LLCJune 21, 2025 | marketbeat.comRigel Pharmaceuticals' SWOT analysis: promising pipeline drives stock potentialJune 14, 2025 | investing.comIs Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?May 29, 2025 | zacks.comWall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?May 28, 2025 | zacks.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comRigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 CongressMay 22, 2025 | prnewswire.comHere's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock NowMay 14, 2025 | zacks.comIs Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?May 13, 2025 | zacks.comUpgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) ForecastsMay 11, 2025 | finance.yahoo.comRigel Pharmaceuticals, Inc. Just Recorded A 370% EPS Beat: Here's What Analysts Are Forecasting NextMay 9, 2025 | uk.finance.yahoo.comEarnings Estimates Rising for Rigel (RIGL): Will It Gain?May 9, 2025 | zacks.comWall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a BetMay 8, 2025 | zacks.comRigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | finanznachrichten.deWhy Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Up 27.08%May 8, 2025 | aaii.comARigel Pharmaceuticals: Q1 Earnings Showcase Growing MomentumMay 7, 2025 | seekingalpha.comRigel Pharmaceuticals (RIGL) Price Target Raised by Cantor Fitzgerald | RIGL Stock NewsMay 7, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRIGL, DVAX, INVA, and MNKD Company DescriptionsDynavax Technologies NASDAQ:DVAX$10.44 -0.30 (-2.79%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$10.44 0.00 (-0.05%) As of 07/15/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Innoviva NASDAQ:INVA$19.96 +0.38 (+1.94%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$20.19 +0.23 (+1.15%) As of 07/15/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$3.85 -0.18 (-4.47%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$3.92 +0.06 (+1.69%) As of 07/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Rigel Pharmaceuticals NASDAQ:RIGL$18.90 -0.45 (-2.33%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$18.70 -0.20 (-1.03%) As of 07/15/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
